<DOC>
	<DOCNO>NCT02450786</DOCNO>
	<brief_summary>There grow interest identify Parkinson 's disease ( PD ) patient mild cognitive impairment ( MCI ) susceptible progress PD dementia ( PDD ) . PD-MCI know significantly correlate low cerebrospinal beta-amyloid 1-42 1-40 level , suggest existence something common Alzheimer 's dementia . PDD show cholinergic deficit Alzheimer 's dementia respond donepezil . The investigator assume PD-MCI patient also cholinergic deficit . Donepezil improve cognition , seem well tolerate worsen parkinsonism patient cognitive impairment . Donepezil produce similar improvement cognition behaviour DLB PDD . This support hypothesis two disorder closely relate clinically neurobiologically . Larger scale , placebo control clinical trial need provide evidence base guide clinical use cholinesterase inhibitor Lewy body disease . It believe earlier intervention , later appearance dementia need low socioeconomic cost improve quality life patient caregiver . The investigator anticipate donepezil may delay development dementia patient PD-MCI .</brief_summary>
	<brief_title>Effect Donepezil Cognition Parkinson 's Disease With Mild Cognitive Impairment ( PD-MCI )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Age 40 year old Clinical diagnosis PD establish Queen Square Brain Bank Criteria Stable dose levodopa least 3 month study enrollment Diagnosis MCI PD accord Movement Disorder Society ( MDS ) task force guideline Diagnosis Dementia Hypersensitivity piperidine derivative Concomitant anticholinergic cholinergic agent Severe cardiac arrhythmia : Sick sinus syndrome , complete AV block , Uncontrolled arrhythmia , history ventricular fibrillation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>